Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25156071,flow rate,"Chromatographic separation was carried out on an Acclaim RSLC120 C18 column (2.1 × 100 mm, 2.2 μm) using a gradient elution consisting of 7.5 mM ammonium acetate and acetonitrile containing 0.1% formic acid (0.4 mL/min flow rate, 7.0 min total run time).","Simultaneous determination of trifolirhizin, (-)-maackiain, (-)-sophoranone, and 2-(2,4-dihydroxyphenyl)-5,6-methylenedioxybenzofuran from Sophora tonkinensis in rat plasma by liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25156071/),[ml] / [min],0.4,13973,DB00672,Chlorpropamide
,25156071,total run time,"Chromatographic separation was carried out on an Acclaim RSLC120 C18 column (2.1 × 100 mm, 2.2 μm) using a gradient elution consisting of 7.5 mM ammonium acetate and acetonitrile containing 0.1% formic acid (0.4 mL/min flow rate, 7.0 min total run time).","Simultaneous determination of trifolirhizin, (-)-maackiain, (-)-sophoranone, and 2-(2,4-dihydroxyphenyl)-5,6-methylenedioxybenzofuran from Sophora tonkinensis in rat plasma by liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25156071/),min,7.0,13974,DB00672,Chlorpropamide
,23225735,total run time,Each sample was run at 0.6 mL/min for a total run time of 2 min per sample.,"Quantitation and pharmacokinetics of 1,4-diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene (U0126) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23225735/),-1·min,2,38853,DB00672,Chlorpropamide
,15845,bioavailability,"With 95% confidence, the mean bioavailability of chlorpropamide from the new formulations was within about 16% of the mean from the reference formulaion, and formulation-related differences were not statistically significant.","Plasma concentrations, bioavailability and dissolution of chlorpropamide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845/),%,16,55966,DB00672,Chlorpropamide
,15845,peak mean concentration,A peak mean concentration of 22.7 mug/ml was reached 3 h after administration of 2 x 100 mg tablets of the new formulation and peak mean concentrations of 26.8 mug/ml and 27.4 mug/ml were reached 3 h and 4 hours after administration of one 250 mg tablet of the new formulation and one 250 mg tablet of the reference formulation respectively.,"Plasma concentrations, bioavailability and dissolution of chlorpropamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845/),[μg] / [ml],22.7,55967,DB00672,Chlorpropamide
,15845,peak mean concentrations,A peak mean concentration of 22.7 mug/ml was reached 3 h after administration of 2 x 100 mg tablets of the new formulation and peak mean concentrations of 26.8 mug/ml and 27.4 mug/ml were reached 3 h and 4 hours after administration of one 250 mg tablet of the new formulation and one 250 mg tablet of the reference formulation respectively.,"Plasma concentrations, bioavailability and dissolution of chlorpropamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845/),[μg] / [ml],26.8,55968,DB00672,Chlorpropamide
,15845,peak mean concentrations,A peak mean concentration of 22.7 mug/ml was reached 3 h after administration of 2 x 100 mg tablets of the new formulation and peak mean concentrations of 26.8 mug/ml and 27.4 mug/ml were reached 3 h and 4 hours after administration of one 250 mg tablet of the new formulation and one 250 mg tablet of the reference formulation respectively.,"Plasma concentrations, bioavailability and dissolution of chlorpropamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845/),[μg] / [ml],27.4,55969,DB00672,Chlorpropamide
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,34.4,67748,DB00672,Chlorpropamide
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,50.2,67749,DB00672,Chlorpropamide
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,5.1,67750,DB00672,Chlorpropamide
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,11.4,67751,DB00672,Chlorpropamide
,3595702,clearance,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [h·kg],2.99,67752,DB00672,Chlorpropamide
,3595702,clearance,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [h·kg],1.60,67753,DB00672,Chlorpropamide
,3595702,volume of distribution,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [kg],126,67754,DB00672,Chlorpropamide
,3595702,volume of distribution,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [kg],106,67755,DB00672,Chlorpropamide
,3595702,unbound fraction,The unbound fraction of chlorpropamide in serum was also higher in the patients (5.7%) than in the healthy subjects (4.4%).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),%,5.7,67756,DB00672,Chlorpropamide
,3595702,unbound fraction,The unbound fraction of chlorpropamide in serum was also higher in the patients (5.7%) than in the healthy subjects (4.4%).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),%,4.4,67757,DB00672,Chlorpropamide
,27902942,flow rate,"Plasma samples were precipitated with acetonitrile and separated using an Eclipse Plus C18 column (100×4.6mm, 1.8-μm) with a mobile phase consisting of 0.1% formic acid in acetonitrile and 0.1% formic acid in water (60:40v/v) at a flow rate of 0.5ml/min.",A simple and sensitive liquid chromatography-tandem mass spectrometry method for trans-ε-viniferin quantification in mouse plasma and its application to a pharmacokinetic study in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27902942/),[ml] / [min],0.5,113865,DB00672,Chlorpropamide
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,3.1,118203,DB00672,Chlorpropamide
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,4.1,118204,DB00672,Chlorpropamide
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,14.8,118205,DB00672,Chlorpropamide
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,10.0,118206,DB00672,Chlorpropamide
,2600795,retention times,"Under these conditions, the retention times of the carboxy and hydroxylated metabolites and the internal standard salicylic acid were 4.6, 6.7, and 8.1 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,4.6,118207,DB00672,Chlorpropamide
,2600795,retention times,"Under these conditions, the retention times of the carboxy and hydroxylated metabolites and the internal standard salicylic acid were 4.6, 6.7, and 8.1 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,6.7,118208,DB00672,Chlorpropamide
,2600795,retention times,"Under these conditions, the retention times of the carboxy and hydroxylated metabolites and the internal standard salicylic acid were 4.6, 6.7, and 8.1 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,8.1,118209,DB00672,Chlorpropamide
,24648255,flow rate,"Chromatographic separation was performed on a Luna CN column with an isocratic mobile phase consisting of distilled water and methanol containing 0.1% formic acid (60:40, v/v) at a flow rate of 0.3 mL/min.","Simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: Application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648255/),[ml] / [min],0.3,137959,DB00672,Chlorpropamide
,24648255,total run time,The total run time was 3.0 min per sample.,"Simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: Application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648255/),[min] / [sample],3.0,137960,DB00672,Chlorpropamide
,28918323,flow rate,The mobile phase consisted of 0.1% formic acid in acetonitrile -0.1% formic acid in water (1:1v/v) and the flow rate was 0.3mL/min.,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),[ml] / [min],0.3,227020,DB00672,Chlorpropamide
,28918323,total chromatographic run time,The total chromatographic run time was 2.5min.,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),min,2.5,227021,DB00672,Chlorpropamide
,28918323,m/z,Detection was performed on a triple quadrupole mass spectrometer equipped with positive-ion electrospray ionization by selected reaction monitoring of the transitions at m/z 720.20>100.15 (for carfilzomib) and m/z 277.05>111.05 (for the internal standard).,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),,720.20,227022,DB00672,Chlorpropamide
>,28918323,m/z,Detection was performed on a triple quadrupole mass spectrometer equipped with positive-ion electrospray ionization by selected reaction monitoring of the transitions at m/z 720.20>100.15 (for carfilzomib) and m/z 277.05>111.05 (for the internal standard).,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),,100.15,227023,DB00672,Chlorpropamide
>,28918323,m/z,Detection was performed on a triple quadrupole mass spectrometer equipped with positive-ion electrospray ionization by selected reaction monitoring of the transitions at m/z 720.20>100.15 (for carfilzomib) and m/z 277.05>111.05 (for the internal standard).,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),,277.05,227024,DB00672,Chlorpropamide
>,28918323,m/z,Detection was performed on a triple quadrupole mass spectrometer equipped with positive-ion electrospray ionization by selected reaction monitoring of the transitions at m/z 720.20>100.15 (for carfilzomib) and m/z 277.05>111.05 (for the internal standard).,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),,111.05,227025,DB00672,Chlorpropamide
,15842554,K(m),"In human liver microsomal incubation studies, the formation of 2-hydroxychlorpropamide (2-OH-chlorpropamide), a major chlorpropamide metabolite in human, has been best described by a one-enzyme model with estimated K(m) and V(max) of 121.7 +/- 19.9 microm and 16.1 +/- 5.0 pmol min(-1) mg(-1) protein, respectively.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),μm,121.7,235078,DB00672,Chlorpropamide
,15842554,V(max),"In human liver microsomal incubation studies, the formation of 2-hydroxychlorpropamide (2-OH-chlorpropamide), a major chlorpropamide metabolite in human, has been best described by a one-enzyme model with estimated K(m) and V(max) of 121.7 +/- 19.9 microm and 16.1 +/- 5.0 pmol min(-1) mg(-1) protein, respectively.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[pM] / [mg·min],16.1,235079,DB00672,Chlorpropamide
,15842554,intrinsic clearances,"In incubation studies using human recombinant CYP isoforms, however, 2-OH-chlorpropamide was formed by both CYP2C9 and CYP2C19 with similar intrinsic clearances (CYP2C9 vs. CYP2C19: 0.26 vs. 0.22 microl min(-1) nmol(-1) protein).","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[μl] / [min·nmol],0.26,235080,DB00672,Chlorpropamide
,15842554,intrinsic clearances,"In incubation studies using human recombinant CYP isoforms, however, 2-OH-chlorpropamide was formed by both CYP2C9 and CYP2C19 with similar intrinsic clearances (CYP2C9 vs. CYP2C19: 0.26 vs. 0.22 microl min(-1) nmol(-1) protein).","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[μl] / [min·nmol],0.22,235081,DB00672,Chlorpropamide
,15842554,nonrenal clearance,"In in vivo clinical trials, eight subjects with the CYP2C9*1/*3 genotype exhibited significantly lower nonrenal clearance [*1/*3 vs.*1/*1: 1.8 +/- 0.2 vs.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,1.8,235082,DB00672,Chlorpropamide
,15842554,metabolic ratios,"2.4 +/- 0.1 ml h(-1) kg(-1), P < 0.05; 95% confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-chlorpropamide in urine: *1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P < 0.05; 95% CI on the difference - 0.9, - 0.1) than did 13 subjects with CYP2C9*1/*1 genotype.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,1.01,235083,DB00672,Chlorpropamide
,15842554,metabolic ratios,"2.4 +/- 0.1 ml h(-1) kg(-1), P < 0.05; 95% confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-chlorpropamide in urine: *1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P < 0.05; 95% CI on the difference - 0.9, - 0.1) than did 13 subjects with CYP2C9*1/*1 genotype.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,0.56,235084,DB00672,Chlorpropamide
,27432781,flow rate,Chromatographic separation was performed using Kinetex C18 column with a gradient mobile phase consisting of water and acetonitrile containing 0.1% formic acid at a flow rate of 0.3 mL/min.,"Assessment of pharmacokinetics, bioavailability and protein binding of anacetrapib in rats by a simple high-performance liquid chromatography-tandem mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27432781/),[ml] / [min],0.3,237717,DB00672,Chlorpropamide
,27432781,fraction of unbound,"The fraction of unbound anacetrapib was determined to be low (ranging from 5.66 to 12.3%), and the absolute oral bioavailability of anacetrapib was 32.7%.","Assessment of pharmacokinetics, bioavailability and protein binding of anacetrapib in rats by a simple high-performance liquid chromatography-tandem mass spectrometry method. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27432781/),%,5.66 to 12.3,237718,DB00672,Chlorpropamide
,27432781,absolute oral bioavailability,"The fraction of unbound anacetrapib was determined to be low (ranging from 5.66 to 12.3%), and the absolute oral bioavailability of anacetrapib was 32.7%.","Assessment of pharmacokinetics, bioavailability and protein binding of anacetrapib in rats by a simple high-performance liquid chromatography-tandem mass spectrometry method. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27432781/),%,32.7,237719,DB00672,Chlorpropamide
